6621 Stock Overview
UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
UniPharma Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$14.00 |
52 Week High | NT$24.75 |
52 Week Low | NT$12.00 |
Beta | 0.61 |
1 Month Change | 5.66% |
3 Month Change | -6.35% |
1 Year Change | -33.01% |
3 Year Change | 0% |
5 Year Change | 11.91% |
Change since IPO | -45.95% |
Recent News & Updates
Recent updates
Shareholder Returns
6621 | TW Healthcare | TW Market | |
---|---|---|---|
7D | -0.7% | 0.5% | 1.5% |
1Y | -33.0% | -2.4% | 26.1% |
Return vs Industry: 6621 underperformed the TW Healthcare industry which returned -2.4% over the past year.
Return vs Market: 6621 underperformed the TW Market which returned 26.1% over the past year.
Price Volatility
6621 volatility | |
---|---|
6621 Average Weekly Movement | 4.2% |
Healthcare Industry Average Movement | 3.9% |
Market Average Movement | 4.2% |
10% most volatile stocks in TW Market | 8.0% |
10% least volatile stocks in TW Market | 1.9% |
Stable Share Price: 6621 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6621's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | n/a | Yu-Shan Wang | https://www.uni-pharma.com |
UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. The company provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. It offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services.
UniPharma Co., Ltd. Fundamentals Summary
6621 fundamental statistics | |
---|---|
Market cap | NT$497.01m |
Earnings (TTM) | -NT$14.14m |
Revenue (TTM) | NT$124.29m |
4.0x
P/S Ratio-35.2x
P/E RatioIs 6621 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6621 income statement (TTM) | |
---|---|
Revenue | NT$124.29m |
Cost of Revenue | NT$54.14m |
Gross Profit | NT$70.15m |
Other Expenses | NT$84.29m |
Earnings | -NT$14.14m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.40 |
Gross Margin | 56.44% |
Net Profit Margin | -11.38% |
Debt/Equity Ratio | 0% |
How did 6621 perform over the long term?
See historical performance and comparison